IntegerBio develops host‑directed therapeutics using its proprietary SYNFERON™ platform, which enables precise, tunable modulation of cytokine signaling to produce durable immune responses. The technology is designed to address viral, oncologic, and inflammatory diseases with flexible dosing and data‑driven discovery, allowing pharmaceutical and biotech partners to generate multiple therapeutic candidates from a single platform.
Funding
$22.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current treatments for viral, oncologic, and inflammatory diseases often target specific pathogens or pathways, resulting in limited efficacy across diverse conditions and the need for multiple separate therapies. Developing broad, host-directed therapeutics that can be safely tuned to different disease contexts remains a major scientific and commercial challenge.
Solution
IntegerBio leverages its proprietary SYNFERON™ tunable technology to create host-directed therapeutics that modulate the immune system in a controlled manner. By engineering cytokine pathways that can be adjusted for potency and duration, the platform aims to provide durable responses across multiple disease categories, including multi-viral infections, cancers, and inflammatory disorders. The company applies data‑focused biology and iterative design cycles to optimize safety and efficacy before advancing candidates into preclinical and clinical development. Partnerships with pharmaceutical and biotech organizations enable the translation of these engineered immune modulators into therapeutic programs tailored to specific clinical needs.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking host‑directed immune therapeutics, as well as research institutions developing treatments for viral, cancer, or inflammatory diseases.
Features
- SYNFERON™ platform that enables precise, tunable modulation of cytokine signaling pathways
- Engineered immune effectors designed for broad applicability across viral, oncologic, and inflammatory indications
- Data‑driven discovery pipeline integrating high‑throughput screening, computational modeling, and systems immunology
- Flexible dosing strategies to achieve durable therapeutic responses while minimizing adverse effects
- Capability to generate multiple therapeutic candidates from a single platform for rapid program diversification